10-Q: PepGen Inc. Q1 2026 Earnings: Reduced R&D Spending, Cash Runway Extended

PepGen Inc. reported a net loss of $17.8 million for Q1 2026, with a significant decrease in R&D expenses and a cash runway extending into the second half of 2027.

Summary

• PepGen Inc. reported a net loss of $17.8 million for the first quarter ended March 31, 2026, a decrease from $30.2 million in the same period last year.
• Research and development expenses significantly decreased by $12.4 million to $13.0 million, primarily due to lower manufacturing costs and personnel-related expenses.
• General and administrative expenses remained stable at $5.9 million.
• The company's cash, cash equivalents, and marketable securities totaled $132.3 million as of March 31, 2026.
• Management estimates that current cash reserves are sufficient to fund operations into the second half of 2027.
• The company continues to advance its PGN-EDODM1 program for DM1, with ongoing Phase 2 trials, while addressing a partial clinical hold from the FDA.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously negative due to the ongoing net losses, accumulated deficit, and the partial FDA clinical hold, despite the positive aspects of reduced R&D spending and an extended cash runway.

Positives

• Significant reduction in R&D expenses, indicating improved cost management.
• Extended cash runway into the second half of 2027, providing financial stability.
• PGN-EDODM1 program continues to progress through clinical trials, with topline data from the 5 mg/kg cohort of FREEDOM2 showing generally well-tolerated results.
• Orphan drug designation and Fast Track designation granted by the FDA and EMA for PGN-EDODM1.

Negatives

• Continued net loss of $17.8 million for the quarter.
• Accumulated deficit of $378.9 million.
• Partial clinical hold from the FDA on the FREEDOM2 study in the U.S. may impact timelines.
• Splicing correction results in the FREEDOM2 study's 5 mg/kg cohort were lower than anticipated, with an outlier patient impacting the mean.
• The company has not generated any revenue from product sales and expects to continue incurring losses.

Risks

• Substantial dependence on the success of PGN-EDODM1, with no products currently approved for sale.
• Need for substantial additional funding to continue product development and operations.
• Uncertainty in clinical trial outcomes, including patient enrollment and demonstration of safety and efficacy.
• Potential delays or difficulties in obtaining regulatory approval, including addressing the FDA's partial clinical hold.
• Reliance on third-party manufacturers and suppliers, which could lead to delays or increased costs.
• Intense competition from other companies developing therapies for similar diseases.
• Potential for adverse side effects or unexpected properties of product candidates.
• Volatility in the company's common stock price.

Future Outlook

PepGen expects its cash, cash equivalents, and marketable securities to be sufficient to fund its currently planned operations into the second half of 2027. The company anticipates continued expenses and operating losses as it progresses with its PGN-EDODM1 program and other research and development activities.

Management Comments

• Management believes that its cash, cash equivalents, and marketable securities as of March 31, 2026, will be sufficient to fund its currently planned operations for at least the next 12 months.
• The company expects its expenses and operating losses will continue as it conducts ongoing preclinical studies and current and planned clinical trials of PGN-EDODM1, continues research and development activities, and incurs costs associated with being a public company.

Industry Context

StockSavvy.ai notes that PepGen operates in the highly competitive clinical-stage biotechnology sector, focusing on rare neuromuscular and neurological diseases. The company's strategy relies heavily on its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, a common approach in the industry to improve drug delivery. The ongoing clinical hold for PGN-EDODM1 in the U.S. highlights the significant regulatory hurdles and scrutiny faced by companies in this space.

Comparison to Industry Standards

• PepGen's R&D spending as a percentage of total operating expenses is high, typical for clinical-stage biotech companies investing heavily in pipeline development.
• The company's net loss and accumulated deficit are consistent with early-stage biotechs that have not yet commercialized products.
• The cash runway into the second half of 2027 is a positive indicator, suggesting prudent financial management, though the need for future capital raises is a common industry challenge.

Legal Proceedings

• A putative shareholder class action lawsuit was filed on June 9, 2025, which was subsequently voluntarily dismissed in November 2025.
• A separate shareholder demand based on similar allegations was withdrawn in December 2025.
• The company is not currently party to any other litigation.

Related Party Transactions

• Technology License Agreement with Oxford University Innovation Limited and Medical Research Council of United Kingdom Research and Innovation, involving upfront payments, milestone payments, and royalties.
• Oxford Science Enterprises, an affiliate of OUI, owned 7.2% of outstanding common stock as of March 31, 2026.
• Entities affiliated with RA Capital Management, L.P. owned 29.1% of outstanding common stock as of March 31, 2026. Two board members are affiliated with RA Capital.
• Fees paid to RA Capital for board service were $11,000 for Q1 2026 and $12,000 for Q1 2025.

Stakeholder Impact

• Shareholders: Continued net losses and accumulated deficit may impact stock value. Extended cash runway provides some stability, but future capital raises could dilute ownership.
• Employees: Continued focus on R&D and potential growth may create opportunities, but financial performance and clinical trial success are critical for job security.
• Creditors: The company's financial position appears stable for the near term, but future funding needs could impact debt servicing if not met.
• Partners/Collaborators: The company's progress in clinical trials and regulatory approvals is crucial for the success of any potential collaborations.

Next Steps

• Continue to work with the FDA to address questions related to the partial clinical hold on the FREEDOM2 study.
• Continue patient enrollment and dosing in the FREEDOM2 study, with expected data from the 10 mg/kg cohort in the second half of 2026.
• Advance the PGN-EDODM1 program through clinical development.
• Manage operating expenses and cash resources to maintain operations into the second half of 2027.

Key Dates

Recommendation

PepGen's stock is currently in a speculative phase, with significant clinical and regulatory risks. While the reduced R&D spending and extended cash runway are positive, the ongoing net losses, accumulated deficit, and the partial FDA clinical hold on its lead program (PGN-EDODM1) present considerable headwinds. The company's future success hinges on navigating these clinical and regulatory challenges. Given the high risk/reward profile, a 'hold' recommendation is appropriate, advising investors to monitor clinical trial progress and regulatory updates closely.

Keywords

PepGen, 10-Q, Biotechnology, Clinical Stage, Neuromuscular Diseases, Neurologic Diseases, Oligonucleotide Therapeutics, PGN-EDODM1, DM1, Clinical Trials, FDA, Financial Results, R&D Expenses, Cash Runway